Apotex announced the U.S. launch of sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, both of which are eligible for 180‑day shared exclusivity. These launches expand Apotex's portfolio of treatment options for adults living with type 2 diabetes mellitus.
Type 2 diabetes affects millions of adults in the United States, and treatment often requires long-term, reliable access to prescribed therapies.
Sitagliptin tablets are AB rated (per FDA's Approved Drug Products with Therapeutic Equivalence Evaluations) to JANUVIA® (Merck) and are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
The product is available in 25 mg, 50 mg, and 100 mg strengths, packaged in 30‑count and 90‑count bottles.
Sitagliptin and metformin hydrochloride tablets are AB rated to JANUMET® (Merck) and are indicated as a prescription medicine that contains a fixed-dose combination of sitagliptin and metformin hydrochloride, sitagliptin and metformin, and can be used as an adjunct to diet and exercise to lower blood sugar in adults with type 2 diabetes. The product is available in 50 mg/500 mg and 50 mg-1,000 mg count bottles.
"Expanding access to high-quality, affordable medicines remain central to our mission," said Christine Baeder, President, Apotex USA and LATAM. "By introducing these products, we are seeking to strengthen the continuity of care for adults managing chronic conditions and supporting the healthcare professionals who rely on consistent, reliable treatment options for their patients."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!